Media Contact

    • 25 July 2017
    • Rosen Comments on Implications of Delay on Passing FDARA

    • Partner David Rosen told Pink Sheet in an article, “FDA Gives Congress Reprieve on Deadline for Passing User Fee Bill,” that most Senators are still pushing to get the FDA Reauthorization Act done prior to October 1, 2017.
    • 14 July 2017
    • Rosen Comments on FDA User Fee Legislation

    • In Modern Healthcare’s article, “House Passes Bipartisan FDA User Fee Bill,” Partner David Rosen discussed the impact of new legislation passed in the House of Representatives that reauthorizes the FDA’s ability to collect user fees from drug and device makers.
    • 24 October 2016
    • Rosen Quoted on Obstacles to Generic EpiPen

    • Partner David Rosen participated in a question and answer session with Reuter’s Westlaw, “Q&A: Foley & Lardner’s David Rosen on Obstacles to Generic EpiPen,” on October 24, 2106.
    • 22 September 2016
    • Rosen Quoted on FDA Requirements for Drug Shelf Life

    • Partner David Rosen was quoted in a Modern Healthcare article, “Extending EpiPen Shelf Life Could be a Relief for Patients, Costly for Mylan,” on September 22, 2016.
    • 25 August 2015
    • Beaver Quoted on FDA Warning

    • Partner Nathan Beaver was quoted in an Inc. article, “Hampton Creek CEO: No Plans to Change Name of ‘Just Mayo’ Despite FDA Warning,” on August 25, 2015.
    • 16 March 2015
    • Beaver Quoted on Food Safety System

    • Partner Nate Beaver was quoted in a Fortune article, “Could This Plan Finally Stop Food Contamination?” on March 16, 2015. The article discussed the Obama Administration’s...
    Filters applied:
    Search phrase entered: